F S Mirza1,2, P Luthra3,4, L Chirch5,4. 1. Division of Endocrinology and Metabolism, Department of Medicine, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030-5456, USA. fmirza@uchc.edu. 2. Department of Medicine, UConn Health, Farmington, CT, 06030, USA. fmirza@uchc.edu. 3. Division of Endocrinology and Metabolism, Department of Medicine, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030-5456, USA. 4. Department of Medicine, UConn Health, Farmington, CT, 06030, USA. 5. Division of Infectious Diseases, UConn Health, Farmington, CT, 06030, USA.
Abstract
PURPOSE: Patients with human immunodeficiency virus (HIV) are living longer with effective antiretroviral therapies and are enjoying near normal life span. Therefore, they are encountering endocrine issues faced by the general population along with those specific to HIV infection. The purpose of this article is to review the common endocrine aspects of HIV infection, and the early detection and management strategies for these complications. METHODS: Recent literature on HIV and endocrine disease was reviewed. RESULTS: HIV can influence endocrine glands at several levels. Endocrine glandular function may be altered by the direct effect of HIV viral proteins, through generation of systemic and local cytokines and the inflammatory response and via glandular involvement with opportunistic infections and HIV-related malignancies. Endocrine disorders seen in people with HIV include metabolic issues related to obesity such as diabetes, hyperlipidemia, lipohypertrophy, lipoatrophy and lipodystrophy and contribute significantly to quality of life, morbidity and mortality. In addition, hypogonadism, osteopenia and osteoporosis are also more prevalent in the patients with HIV. Although disorders of hypothalamic-pituitary-adrenal axis resulting in adrenal insufficiency can be life threatening, these along with thyroid dysfunction are being seen less commonly in the antiretroviral therapy (ART) era. ARTs have greatly improved life expectancy in people living with HIV but can also have adverse endocrine effects. CONCLUSIONS: Clinicians need to have a high index of suspicion for endocrine abnormalities in people with HIV as they can be potentially life threatening if untreated. Endocrine evaluation should be pursued as in the general population, with focus on prevention, early detection and treatment to improve quality of life and longevity.
PURPOSE:Patients with human immunodeficiency virus (HIV) are living longer with effective antiretroviral therapies and are enjoying near normal life span. Therefore, they are encountering endocrine issues faced by the general population along with those specific to HIV infection. The purpose of this article is to review the common endocrine aspects of HIV infection, and the early detection and management strategies for these complications. METHODS: Recent literature on HIV and endocrine disease was reviewed. RESULTS:HIV can influence endocrine glands at several levels. Endocrine glandular function may be altered by the direct effect of HIV viral proteins, through generation of systemic and local cytokines and the inflammatory response and via glandular involvement with opportunistic infections and HIV-related malignancies. Endocrine disorders seen in people with HIV include metabolic issues related to obesity such as diabetes, hyperlipidemia, lipohypertrophy, lipoatrophy and lipodystrophy and contribute significantly to quality of life, morbidity and mortality. In addition, hypogonadism, osteopenia and osteoporosis are also more prevalent in the patients with HIV. Although disorders of hypothalamic-pituitary-adrenal axis resulting in adrenal insufficiency can be life threatening, these along with thyroid dysfunction are being seen less commonly in the antiretroviral therapy (ART) era. ARTs have greatly improved life expectancy in people living with HIV but can also have adverse endocrine effects. CONCLUSIONS: Clinicians need to have a high index of suspicion for endocrine abnormalities in people with HIV as they can be potentially life threatening if untreated. Endocrine evaluation should be pursued as in the general population, with focus on prevention, early detection and treatment to improve quality of life and longevity.
Entities:
Keywords:
Antiretroviral therapy; Bone disease; Diabetes; Endocrinopathy; Human immunodeficiency virus; Hyperlipidemia; Lipodystrophy
Authors: Sara E Dolan; Walter Frontera; Jamie Librizzi; Karin Ljungquist; Sandra Juan; Robert Dorman; Morgan E Cole; Jenna R Kanter; Steven Grinspoon Journal: Arch Intern Med Date: 2006-06-12
Authors: Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey Journal: J Infect Dis Date: 2015-05-05 Impact factor: 5.226
Authors: Richard H Haubrich; Sharon A Riddler; A Gregory DiRienzo; Lauren Komarow; William G Powderly; Karin Klingman; Kevin W Garren; David L Butcher; James F Rooney; David W Haas; John W Mellors; Diane V Havlir Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Michael Bergman; Muhammad Abdul-Ghani; João Sérgio Neves; Mariana P Monteiro; Jose Luiz Medina; Brenda Dorcely; Martin Buysschaert Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Gabriel Spieler; Andrew O Westfall; Dustin M Long; Andrea Cherrington; Greer A Burkholder; Nicholas Funderburg; James L Raper; Edgar T Overton; Amanda L Willig Journal: AIDS Date: 2022-08-10 Impact factor: 4.632
Authors: J Mellin; M Le Prevost; J Kenny; K Sturgeon; L C Thompson; C Foster; H H Kessler; Nandu Goswami; N Klein; A Judd; H Castro Journal: Front Cardiovasc Med Date: 2022-03-01